Rhinomed Limited reported earnings results for the half year ended December 31, 2022. For the half year, the company reported sales was AUD 3.38 million compared to AUD 3.75 million a year ago. Net loss was AUD 4.65 million compared to AUD 3.25 million a year ago.

Basic loss per share from continuing operations was AUD 0.0163 compared to AUD 0.0128 a year ago. Diluted loss per share from continuing operations was AUD 0.0163 compared to AUD 0.0128 a year ago.